EHVA’s programme primary goals are to:

  • To develop a Multidisciplinary Vaccine Platform (MVP) for prophylactic and therapeutic HIV vaccines
  • To move at least two novel prophylactic vaccine candidates to clinical development
  • To identify immune correlates associated with control of HIV replication following immunological intervention
  • To establish astrong scientific basis for further development of EHVA vaccine candidates in larger clinical trials

EHVA’s multidisciplinary research platforms encompass all aspects of vaccine development from early-stage discovery to clinical trials

Goals of the Discovery Platform include generating novel vaccine candidates. Participating organisations specialise in inducing potent neutralising antibodies and non-neutralising antibodies and T-cell responses.

Goals of the Immune Profiling Platform include developing methods to that provide a profile of the immune response generated by a vaccine candidate.

Goals of the Data Management/Integration/Down-Selection Platform include providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines.

Goals of the Clinical Trials Platform include accelerating the clinical development of novel vaccines and developing tools to predict poor or low efficacy of a candidate early in the process.

News

  • Sunday 23 July 2017, 12.30 – 14.30 EHVA Satellite symposium at IAS 2017

    For participants registered at the IAS meeting, EHVA is organising a satellite symposium to provide an overview of the latest developments in HIV prevention broadly, and prophylactic and therapeutic HIV vaccines in particular, as well as introduce key areas of work for EHVA. 

  • EHVA 1st year Publishable Summary
  • IAS 2017 Conference on HIV Pathogenesis, Treatment and Prevention, Paris 23-26 July 2017

    IAS2017

europa  

This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032